title: Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty.
abstract: OBJECTIVE
  To compare the efficacy of goserelin 10.8 mg (Zoladex LA-ZLA) administered 9-12 weekly with 3.6 mg (Zoladex-Z) given monthly in suppressing pubertal development, and effect on body mass index (BMI).
  
  
  METHODS
  Children with central precocious puberty (CPP) treated with Z (n = 34) or ZLA (n = 28) were studied retrospectively. Pubertal scores and BMI SDS during 24 months' treatment were compared.
  
  
  RESULTS
  To attain adequate pubertal suppression, more patients on ZLA than Z required increase in injection frequency (p = 0.02) and this was so for 7/8 patients with a structural aetiology for CPP on ZLA and 2/8 on Z. A greater proportion of patients on ZLA had BMI >+2 SDS before (p = 0.05), and at 18 and 24 months (p = 0.02 and 0.04). BMI SDS transiently increased during the first 6 months on ZLA (p = 0.04).
  
  
  CONCLUSIONS
  Both Z and ZLA were effective in suppressing puberty. To achieve adequate suppression, increased injection frequency was more likely with ZLA than Z, and particularly in patients with structural defects. Children with CPP had an elevated BMI at the onset of therapy and ZLA had a transient positive influence on BMI.
authors.affiliation: Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, UK.
authors.forename: H
authors.initials: H
authors.lastname: Isaac
authors.forename: L
authors.initials: L
authors.lastname: Patel
authors.forename: S
authors.initials: S
authors.lastname: Meyer
authors.forename: C M
authors.initials: CM
authors.lastname: Hall
authors.forename: C
authors.initials: C
authors.lastname: Cusick
authors.forename: D A
authors.initials: DA
authors.lastname: Price
authors.forename: P E
authors.initials: PE
authors.lastname: Clayton
mesh_terms: D001827:Body Height / Q000187:drug effects; D015992:Body Mass Index; D002648:Child; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D017273:Goserelin / Q000008:administration & dosage*; D048788:Growth and Development / Q000187:drug effects; D006801:Humans; D008297:Male; D011629:Puberty, Precocious / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone